Incyte Corporation (NASDAQ:INCY – Get Free Report) has received an average recommendation of “Hold” from the twenty-five ratings firms that are covering the firm, MarketBeat reports. Fourteen investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $134.38.
INCY has been the subject of several research reports. Stifel Nicolaus increased their price target on shares of Incyte from $145.00 to $157.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Canaccord Genuity Group began coverage on shares of Incyte in a research report on Thursday, August 20th. They issued a “buy” rating and a $152.00 price objective on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of Incyte in a research report on Friday, September 11th. Raymond James Financial set a $152.00 price target on shares of Incyte in a research note on Friday, October 16th. Finally, Royal Bank Of Canada raised their price target on shares of Incyte from $114.00 to $117.00 and gave the stock a “sector perform” rating in a research note on Friday, October 30th.
Check Out Our Latest Stock Report on Incyte
Insider Transactions at Incyte
In other Incyte news, insider Pablo Cagnoni sold 2,642 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $112.71, for a total transaction of $297,779.82. Following the completion of the transaction, the insider directly owned 183,200 shares of the company’s stock, valued at approximately $20,648,472. This represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total value of $72,565.60. Following the completion of the sale, the insider directly owned 21,126 shares of the company’s stock, valued at $2,513,148.96. This represents a 2.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 254,139 shares of company stock valued at $30,098,844 in the last three months. 16.20% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of INCY. Fiduciary Financial Advisors purchased a new stake in Incyte during the 2nd quarter valued at about $26,000. Provenance Wealth Advisors LLC purchased a new position in shares of Incyte during the third quarter valued at about $33,000. Continuum Advisory LLC bought a new position in shares of Incyte in the 2nd quarter worth approximately $36,000. Latitude Advisors LLC bought a new stake in shares of Incyte during the 3rd quarter valued at $39,000. Finally, Meeder Asset Management Inc. grew its stake in shares of Incyte by 518.5% in the 3rd quarter. Meeder Asset Management Inc. now owns 334 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 280 shares during the last quarter. 96.97% of the stock is currently owned by institutional investors.
Incyte Trading Down 1.1%
Shares of Incyte stock opened at $114.63 on Thursday. The business’s fifty day simple moving average is $118.49 and its 200 day simple moving average is $109.37. Incyte has a 12 month low of $89.25 and a 12 month high of $132.60. The firm has a market capitalization of $23.37 billion, a P/E ratio of 60.97, a price-to-earnings-growth ratio of 4.09 and a beta of 0.78.
Incyte (NASDAQ:INCY – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.93) by $0.33. The firm had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The business’s revenue was up 14.0% compared to the same quarter last year. During the same period last year, the firm posted $2.26 EPS. Analysts predict that Incyte will post 2.29 EPS for the current fiscal year.
About Incyte
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Recommended Stories
- Five stocks we like better than Incyte
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
